If you need more lookups,
subscriptions start at $34 USD/month.
Paul Dekker Location
North Brabant, Netherlands
Paul Dekker Work
2020 -now CEO at BodySwitch @
2016 -2020 Owner and Director @
2016 -now Company Owner @ D2P Capital & Consult
2010 -2016 VP R and D Finance @
2004 -2010 VP R and D Finance @
2001 -2004 Chief Financial Officer @ Akzo Nobel Business Unit Diosynth
1998 -2001 Sr. Director Research and Development control @
1994 -1998 Directeur Financier @
1989 -1994 Financial Analyst Logistics and Manufacturing @
1987 -1989 Finance Manager Computing center @
Paul Dekker Education
INSEAD
(Young executive)
1998-1998
Universiteit van Tilburg
(Business Economics)
1982-1987
St Odulphus Lyceum 1976-1982
Sint Paulus school 1970-1976
Paul Dekker Skills
Pharmaceutical Industry
Biotechnology
Clinical Development
R&D
Biopharmaceuticals
Lifesciences
Regulatory Affairs
Life Sciences
Technology Transfer
Clinical Trials
Vaccines
FDA
Oncology
GMP
Pharmaceutics
Cross-functional Team Leadership
GCP
Medical Devices
Immunology
Quality Assurance
R&D planning
Clinical Research
Validation
R&D funding
Licensing
Drug Development
New Business Development
Venture Capital
Operational Excellence
Continuous Improvement
Strategy
Management
Change Management
Business Strategy
Leadership
Logistics
Business Development
Research And Development R&D
Microsoft Office
Cross Functional Team Leadership
Financial Analysis
Project Management
Research and Development
Leefstijlgeneeskunde
Orthomoleculair
Master Franchising
Paul Dekker Summary
Paul Dekker, based in North Brabant, Netherlands, is currently a CEO at BodySwitch at BodySwitch. Paul Dekker brings experience from previous roles at BodySwitch, D2P Capital & Consult, GlaxoSmithKline Biologicals and UCB Pharma. Paul Dekker holds a 1998 - 1998 INSEAD. With a robust skill set that includes Pharmaceutical Industry, Biotechnology, Clinical Development, R&D, Biopharmaceuticals and more. Paul Dekker has 1 emails and 2 mobile phone numbers on RocketReach.
Looking for a different Paul Dekker?
Find contact details for 700 million professionals.